EA007656B1 - Клонированный штамм вируса осповакцины, способ его получения и применение штамма в качестве вакцины - Google Patents
Клонированный штамм вируса осповакцины, способ его получения и применение штамма в качестве вакцины Download PDFInfo
- Publication number
- EA007656B1 EA007656B1 EA200301151A EA200301151A EA007656B1 EA 007656 B1 EA007656 B1 EA 007656B1 EA 200301151 A EA200301151 A EA 200301151A EA 200301151 A EA200301151 A EA 200301151A EA 007656 B1 EA007656 B1 EA 007656B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- strain
- virus
- vaccine
- vaccinia virus
- virulence
- Prior art date
Links
- 241000700647 Variola virus Species 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 29
- 229960005486 vaccine Drugs 0.000 title abstract description 65
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 36
- 238000004113 cell culture Methods 0.000 claims abstract description 19
- 230000001018 virulence Effects 0.000 claims abstract description 17
- 230000001681 protective effect Effects 0.000 claims abstract description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 11
- 230000012010 growth Effects 0.000 claims abstract description 9
- 238000010367 cloning Methods 0.000 claims abstract description 7
- 230000005847 immunogenicity Effects 0.000 claims abstract description 7
- 230000028993 immune response Effects 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 241000699670 Mus sp. Species 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102100022443 CXADR-like membrane protein Human genes 0.000 claims 3
- XXQGYGJZNMSSFD-UHFFFAOYSA-N 2-[2-(dimethylcarbamoyl)phenoxy]acetic acid Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)=O XXQGYGJZNMSSFD-UHFFFAOYSA-N 0.000 claims 2
- 101000901723 Homo sapiens CXADR-like membrane protein Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 abstract description 8
- 230000029087 digestion Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940125575 vaccine candidate Drugs 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 244000309466 calf Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940083538 smallpox vaccine Drugs 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 0 CCCC(C1)(CC1(CC1)CC(C(C2)C(C*)C(C)C3C(C)CC3C)C12CCC(CC1)C2)CCCCC(CCC)(*COC)CCC12C=C Chemical compound CCCC(C1)(CC1(CC1)CC(C(C2)C(C*)C(C)C3C(C)CC3C)C12CCC(CC1)C2)CCCCC(CCC)(*COC)CCC12C=C 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/840,751 US6723325B1 (en) | 2001-04-23 | 2001-04-23 | Smallpox vaccine |
| PCT/US2002/012616 WO2002085411A1 (en) | 2001-04-23 | 2002-04-23 | Smallpox vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200301151A1 EA200301151A1 (ru) | 2004-10-28 |
| EA007656B1 true EA007656B1 (ru) | 2006-12-29 |
Family
ID=25283120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200301151A EA007656B1 (ru) | 2001-04-23 | 2002-04-23 | Клонированный штамм вируса осповакцины, способ его получения и применение штамма в качестве вакцины |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6723325B1 (https=) |
| EP (1) | EP1381389B1 (https=) |
| JP (1) | JP4397591B2 (https=) |
| KR (1) | KR20040063083A (https=) |
| CN (1) | CN1527722A (https=) |
| AU (1) | AU2002258910B2 (https=) |
| BR (1) | BR0209145A (https=) |
| CA (1) | CA2444747C (https=) |
| CZ (1) | CZ305819B6 (https=) |
| EA (1) | EA007656B1 (https=) |
| ES (1) | ES2546612T3 (https=) |
| HU (1) | HU228401B1 (https=) |
| IL (2) | IL158549A0 (https=) |
| MA (1) | MA26270A1 (https=) |
| MX (1) | MXPA03009711A (https=) |
| NZ (1) | NZ529265A (https=) |
| PL (1) | PL212117B1 (https=) |
| WO (1) | WO2002085411A1 (https=) |
| ZA (1) | ZA200309084B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2496149C1 (ru) * | 2012-06-19 | 2013-10-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ оценки противооспенной активности лечебно-профилактических препаратов |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US6723325B1 (en) * | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| KR100859345B1 (ko) * | 2006-12-12 | 2008-09-19 | 씨제이제일제당 (주) | 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신 |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| JPS60202827A (ja) | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
| US5614193A (en) * | 1991-11-14 | 1997-03-25 | The United States Of America As Represented By The Secretary Of The Army | Hantavirus vaccine |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
-
2001
- 2001-04-23 US US09/840,751 patent/US6723325B1/en not_active Expired - Lifetime
-
2002
- 2002-04-23 PL PL373958A patent/PL212117B1/pl unknown
- 2002-04-23 KR KR10-2003-7013866A patent/KR20040063083A/ko not_active Ceased
- 2002-04-23 HU HU0303878A patent/HU228401B1/hu unknown
- 2002-04-23 BR BR0209145-3A patent/BR0209145A/pt active Search and Examination
- 2002-04-23 CN CNA028126335A patent/CN1527722A/zh active Pending
- 2002-04-23 EP EP02728888.5A patent/EP1381389B1/en not_active Expired - Lifetime
- 2002-04-23 AU AU2002258910A patent/AU2002258910B2/en not_active Ceased
- 2002-04-23 EA EA200301151A patent/EA007656B1/ru not_active IP Right Cessation
- 2002-04-23 IL IL15854902A patent/IL158549A0/xx unknown
- 2002-04-23 JP JP2002582984A patent/JP4397591B2/ja not_active Expired - Fee Related
- 2002-04-23 ES ES02728888.5T patent/ES2546612T3/es not_active Expired - Lifetime
- 2002-04-23 WO PCT/US2002/012616 patent/WO2002085411A1/en not_active Ceased
- 2002-04-23 CZ CZ2003-3184A patent/CZ305819B6/cs not_active IP Right Cessation
- 2002-04-23 MX MXPA03009711A patent/MXPA03009711A/es active IP Right Grant
- 2002-04-23 NZ NZ529265A patent/NZ529265A/en not_active IP Right Cessation
- 2002-04-23 CA CA2444747A patent/CA2444747C/en not_active Expired - Lifetime
-
2003
- 2003-05-27 US US10/445,671 patent/US7115270B2/en not_active Expired - Lifetime
- 2003-10-22 IL IL158549A patent/IL158549A/en unknown
- 2003-11-17 MA MA27401A patent/MA26270A1/fr unknown
- 2003-11-21 ZA ZA2003/09084A patent/ZA200309084B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
Non-Patent Citations (2)
| Title |
|---|
| HENDERSON et al. Smallpox as a Biological Weapon. Medical and Public Health Management. JAMA. 09 June 1999, Vol. 281, No. 22, pages 2127-2137, see entire document, especially page 2131, third column, and page 2136, second column * |
| KUTINOVA et al. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine. 1995, Vol. 13, No. 5, pages 487-493, see entire document, expecially figure 3, lines 7-9, and page 487-488 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2496149C1 (ru) * | 2012-06-19 | 2013-10-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ оценки противооспенной активности лечебно-профилактических препаратов |
Also Published As
| Publication number | Publication date |
|---|---|
| US7115270B2 (en) | 2006-10-03 |
| JP4397591B2 (ja) | 2010-01-13 |
| EP1381389A1 (en) | 2004-01-21 |
| HUP0303878A3 (en) | 2010-01-28 |
| ES2546612T3 (es) | 2015-09-25 |
| KR20040063083A (ko) | 2004-07-12 |
| WO2002085411A1 (en) | 2002-10-31 |
| MXPA03009711A (es) | 2005-03-07 |
| US6723325B1 (en) | 2004-04-20 |
| PL373958A1 (en) | 2005-09-19 |
| AU2002258910B2 (en) | 2007-10-25 |
| EP1381389B1 (en) | 2015-08-26 |
| CA2444747A1 (en) | 2002-10-31 |
| US20060153873A1 (en) | 2006-07-13 |
| CZ20033184A3 (cs) | 2004-04-14 |
| ZA200309084B (en) | 2005-01-26 |
| HU228401B1 (en) | 2013-03-28 |
| CA2444747C (en) | 2018-04-17 |
| PL212117B1 (pl) | 2012-08-31 |
| NZ529265A (en) | 2006-04-28 |
| HK1062804A1 (zh) | 2004-11-26 |
| EA200301151A1 (ru) | 2004-10-28 |
| IL158549A (en) | 2009-07-20 |
| MA26270A1 (fr) | 2004-09-01 |
| BR0209145A (pt) | 2005-04-19 |
| IL158549A0 (en) | 2004-05-12 |
| HUP0303878A2 (hu) | 2004-03-01 |
| CN1527722A (zh) | 2004-09-08 |
| EP1381389A4 (en) | 2004-07-28 |
| JP2005503126A (ja) | 2005-02-03 |
| CZ305819B6 (cs) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003239805B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| US7645456B2 (en) | Vaccinia virus strains | |
| JP5988463B2 (ja) | Ｍｖａによる病原体からの即時保護 | |
| EA007656B1 (ru) | Клонированный штамм вируса осповакцины, способ его получения и применение штамма в качестве вакцины | |
| AU2002258910A1 (en) | Smallpox vaccine | |
| Gellin et al. | Measles: state of the art and future directions | |
| HK1062804B (en) | Smallpox vaccine | |
| RU2781070C1 (ru) | Живая аттенуированная культуральная вакцина для профилактики натуральной оспы и других ортопоксвирусных инфекций на основе вируса осповакцины и способы ее получения и применения | |
| Kara | Questions on Immunization and Vaccination and Short Answers | |
| SU1225579A1 (ru) | Способ профилактики респираторно-синцитиальной инфекции | |
| Seal | Prevention of Smallpox by Vaccination and Revaccination: A Critical Study | |
| Melnick | Poliomyelitis vaccination: what are the options? | |
| Stuart et al. | Encephalitis in man following the use of yellow fever immunizing vaccines: a review of the literature |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |